INSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Inspire Medical Systems Inc (INSP) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown strong financial performance in its latest quarter, significant uncertainties around reimbursement coding changes, reduced analyst price targets, and a lack of clear trading signals make this stock a hold rather than a buy. The investor's capital is better preserved for opportunities with more stable growth and fewer risks.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 69.738. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downtrend. Key support is at 53.95, and resistance levels are at 79.078 and 86.84. Overall, the technical indicators suggest caution.
Positive sentiment from KeyBanc Capital Markets regarding CMS's potential addition of new codes for Inspire V implants. Analysts view the CMS coding development as a positive signal for future revenue. The company projects a revenue outlook of $950 million to $1 billion for 2026 despite challenges.
Multiple analysts have downgraded the stock and significantly reduced price targets, citing reimbursement uncertainties and coding challenges. The transition to CPT code 64582 with the -52 modifier is expected to reduce physician reimbursement, potentially pressuring adoption. Guidance for FY2026 has been lowered, raising concerns about growth visibility.
In Q4 2025, Inspire Medical Systems reported strong financial performance: Revenue increased by 12.25% YoY to $269.08M, Net Income surged by 286.36% YoY to $136.09M, EPS grew by 301.72% YoY to 4.66, and Gross Margin improved to 86.59% (up 1.88% YoY). Despite these strong results, forward guidance has been revised downward, creating uncertainty.
Analysts have a mixed to negative view on the stock. Recent downgrades and price target reductions reflect concerns over reimbursement challenges and reduced growth visibility. Price targets now range from $60 to $95, with most analysts maintaining Neutral or Hold ratings. The lowered FY2026 guidance has further eroded confidence in the company's growth trajectory.
